Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Gains from Investment Securities (2020)

Design Therapeutics' Gains from Investment Securities history spans 1 years, with the latest figure at $1.6 million for Q4 2020.

  • For Q4 2020, Gains from Investment Securities changed N/A year-over-year to $1.6 million; the TTM value through Dec 2020 reached $1.6 million, changed N/A, while the annual FY2024 figure was $100000.0, N/A changed from the prior year.
  • Gains from Investment Securities for Q4 2020 was $1.6 million at Design Therapeutics.
  • Across five years, Gains from Investment Securities topped out at $1.6 million in Q4 2020 and bottomed at $1.6 million in Q4 2020.